HCV in Women

CE / CME

Hepatitis C in Women: Updated Guidance on Screening and Management

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Released: December 01, 2020

Expiration: November 30, 2021

Tatyana Kushner
Tatyana Kushner, MD, MSCE

Activity

Progress
1
Course Completed

In this module, Tatyana Kushner, MD, MSCE, reviews how rising rates of HCV infection in young women have led to updated guidance on screening during pregnancy and for all individuals in the United States.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many women with HCV do you provide care for in a typical week?

What are the current American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) recommendations for HCV screening during pregnancy?

Which of the following statements is correct based on available data regarding the effects of maternal HCV infection on pregnancy/birth outcomes?

When should infants born to mothers with HCV infection be tested for HCV antibodies?